Our Pipeline

Program

Therapeutic Area

Discovery

Development

Hit to lead

Optimization

Preclinic

Phase 1

Phase 2

GI restricted TGF-β inhibitor

 

Crohn´s Disease
Lung-restricted TGF-β inhibitor
Idiopathic Pulmonary Fibrosis